Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
NOVEL ADAMTS13 MUTATIONS IN A PATIENT OF INHERITED THROMBOTIC THROMBOCYTOPENIC PURPURA
26 ledna, 2021 8:54 pmAuthor(s): Li Zhou, Xinhui Zhang, Shanglong Feng, Xing Hu, Changcheng Zheng EHA Library. Zhou L. Jun 15, 2019; 267101; PS1484...
EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION
26 ledna, 2021 8:54 pmAuthor(s): Anait Melikyan, Elena Egorova, Elena Pustovaya, Tamara Kolosheinova, Elena Ladygina, et al. EHA Library. Melikyan A. Jun 15, 2019;...
ADULT ONSET HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA WITH A NOVEL ADAMTS13 MUTATION
26 ledna, 2021 8:54 pmAuthor(s): Julian Freue, Belen Rosales Ostriz, Marcos Martin, Reinaldo Campestri EHA Library. Freue J. Jun 15, 2019; 266715; PS1098 ...
ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 × 109L
26 ledna, 2021 8:54 pmAuthor(s): Mariasanta Napolitano, Giuseppe Avvisati, Monica Carpenedo, Giancarlo Castaman, Elisabetta Cerchiara, et al. EHA Library. Siragusa S. Jun 14, 2019;...
Novinky v diagnostice a léčbě imunitní trombocytopenie
26 ledna, 2021 8:54 pmV rámci každoročního kongresu Evropské hematologické společnosti, který se konal ve dnech 13.–16. června 2019 v Amsterdamu (Nizozemsko), bylo prezentováno několik velmi zajímavých...
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB < 10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL
26 ledna, 2021 8:54 pmAuthor(s): Francisco Cervantes, Heinz Gisslinger, Atanas Radinoff, et. al. EHA Library. Jun 15, 2019; 267082; PS1465 Session topic: 16....
SURVIVAL OUTCOMES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: A POPULATION- -BASED COHORT STUDY IN SWEDEN AND NORWAY
26 ledna, 2021 8:53 pmAuthor(s): Frida Schain, Emese Vago, Jianming He, et. al. EHA Library. Jun 15, 2019; 267080; PS1463 Session topic: 16....
EARLY SPLEEN RESPONSE IS A GOOD PROGNOSTIC FACTOR OF RUXOLINIB OUTCOME IN PATIENTS WITH MYELOFIBROSIS
26 ledna, 2021 8:53 pmAuthor(s): Elza Lomaia, Nadiya Siordiya, Georgy Dimov, et. al. EHA Library. May 16, 2019; 268118; PB2207 Session topic: 16....
Novinky z kongresu: Myeloproliferatívna neoplázia
26 ledna, 2021 8:53 pmPo šiestich rokoch sa kongres európskej hematologickej asociácie vrátil do hlavného mesta Holandska. Program kongresu zahŕňal všetky podkategórie hematológie a choroby...
SAFETY AND CLINICAL ACTIVITY OF AMV564, A CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 1 FIRST-IN-HUMAN TRIAL
26 ledna, 2021 8:53 pmAuthor(s): P. Westervelt, G. J. Roboz, J. E. Cortes, J. K. Altman, V. G. Oehler, et al. EHA Library. Westervelt...